Analyst Price Target is $4.25
▲ +1,920.92% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Nemaura Medical in the last 3 months. The average price target is $4.25, with a high forecast of $6.00 and a low forecast of $2.50. The average price target represents a 1,920.92% upside from the last price of $0.21.
Current Consensus is
The current consensus among 2 contributing investment analysts is to buy stock in Nemaura Medical. This Buy consensus rating has held steady for over two years.
Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.